TITLE: Novel Low Density Lipoprotein Nanocarriers for Targeted Delivery of Anticancer
Molecules to Cancer
INVENTORS: Ian Corbin
TECHNOLOGY: Biologicals
UTSD: 2650
SUMMARY: This invention is a novel combination of two natural products for effective anti-liver
cancer therapy. It is known that many types of cancer cells express LDL receptor on the cell
surface. Therefore, human low density lipoprotein (LDL) was used as a nanocarrier which can
be internalized by normal and cancerous liver cells and then released in intracellular
compartments for intracellular targeted drug delivery. This technology replaces the tri-glycerol
and cholesterol core in normal LDL particles with a molecule of known anticancer properties.
The engineered nanoproducts possess enhanced physical and oxidative stability over its native
counterparts. They have significantly longer shelf life with preserved integrity and biological
activities. The testing data from in vitro study demonstrated strong anti-cancer activity against a
hepatoma cell line while leaving normal cells unharmed. This targeted intracellular delivery
technology of anticancer compounds might be useful for many other types of cancers. It avoids
side effects from traditional direct injection of LDL based therapy, such as leakage of LDL core
components during the course of plasma transportation.
Please contact the Office for Technology Development for more details:
Phone: 214-648-1816
Email: TechnologyDevelopment@utsouthwestern.edu
Please reference UT Southwestern Case Number: 2650